CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of C402-CD19-CAR, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Targeting CD19 in Subjects With Relapsed or Refractory Large B-cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06830031
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:41.597964+00:00
Published At: 2025-06-13T00:00:00+00:00
Record Updated At: 2025-06-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Diffuse Large B-cell-lymphoma", "DLBCL, Nos Genetic Subtypes", "Follicular Lymphoma Grade 3B", "PMBL", "HGBL With MYC and BCL2 and/or BCL6 Rearrangements", "HGBL, Nos"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-13"
protocolSection.identificationModule.nctId: "NCT06830031"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of C402-CD19-CAR, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Targeting CD19 in Subjects With Relapsed or Refractory Large B-cell Lymphoma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.